Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years. NICE technology appraisal guidance 1192
National Institute for Health and Care Excellence (NICE)
Record ID 32018016046
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta1192
Year Published:
2026
URL for published report:
https://www.nice.org.uk/guidance/ta1192
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Neurofibroma, Plexiform
- Child
- Adolescent
- Protein Kinase Inhibitors
- Antineoplastic Agents
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
3rd floor, 3 Piccadilly Place, Manchester, M1 3BN
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.